Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Cboe Europe  -  11:00 2022-10-03 am EDT
773.60 DKK   +1.60%
12:32pNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
10:11aNOVO NORDISK : Barclays reaffirms its Buy rating
MD
08:37aNovo Nordisk A/S – Share repurchase programme
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

08/08/2022 | 11:07am EDT

Bagsværd, Denmark, 8 August 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonAndreas Fibig
2 Reason for the notification
a)Position/statusMember of the Board of Directors
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
ADRs

 Identification codeNVO
b)Nature of the transactionPurchase of ADRs
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 731.87249 ADRs 
 DKK 732.080.399 ADRs 
    
d)Aggregated information
  • Aggregated volume
  • Price


249.399 ADRs

DKK 731.87
e)Date of the transaction2022-08-03
f)Place of the transactionNew York Stock Exchange

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.

Further information

Media:  
Ambre Brown Morley+45 3079 9289abmo@novonordisk.com
Natalia Salomao Abrahao (US)+1 848 304 1027niaa@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com


Company announcement No 64 / 2022

Attachment


Primary Logo


© GlobeNewswire 2022
All news about NOVO NORDISK A/S
12:32pNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
10:11aNOVO NORDISK : Barclays reaffirms its Buy rating
MD
08:37aNovo Nordisk A/S – Share repurchase programme
GL
08:03aOnce-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with..
GL
09/29European ADRs Move Lower in Thursday Trading
MT
09/29Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT
09/28European ADRs Move Higher in Wednesday Trading
MT
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/22Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint
MT
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 171 B 22 581 M 22 581 M
Net income 2022 54 527 M 7 185 M 7 185 M
Net cash 2022 1 098 M 145 M 145 M
P/E ratio 2022 31,3x
Yield 2022 1,53%
Capitalization 1 723 B 227 B 227 B
EV / Sales 2022 10,0x
EV / Sales 2023 8,77x
Nbr of Employees 50 816
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 761,40 DKK
Average target price 836,08 DKK
Spread / Average Target 9,81%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.59%227 057
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296